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Abstract: With the availability of new biological therapies there is the need of more accurate diagnostic tools to non-
invasively assess the presence of their targets. In this scenario nuclear medicine offers many radiopharmaceuticals for 
SPECT or PET imaging of many pathological conditions. The availability of monoclonal antibodies provides tools to 
target specific antigens involved in angiogenesis, cell cycle or modulation of the immune systems. The radiolabelling of 
such therapeutic mAbs is a promising method to evaluate the antigenic status of each cancer lesion or inflamed sites 
before starting the therapy. It may also allow to perform follow-up of such biological therapies. In the present review we 
provide an overview of the most studied radiolabelled antibodies for therapy decision making and follow-up of patients 
affected by cancer and other pathological conditions. 
Keywords: Immunoscintigraphy, Nuclear medicine, Personalized medicine, Radiolabelled mAbs, Radiopharma- 
ceuticals. 
INTRODUCTION 
In the last decade, nuclear medicine has been 
routinely used in the field of oncology and inflammatory 
diseases because of its diagnostic utility, but also for its 
great contribution to the evaluation of disease activity. 
This is relevant, since in many cases, several 
therapeutic options are available for different activity 
states and early and appropriate treatment is 
necessary (1). Indeed, recent advances in the 
development of new radiopharmaceuticals have 
significantly contributed to the identification of 
molecular pathways, responsible for the physiological, 
biochemical and structural changes, a step forward to 
personalized therapy [2, 3].  
This also helped to develop several biological 
therapies that have rapidly entered the market and are 
now available for both cancer and inflammatory 
disease, such as somatostatin, estrogen analogues, 
hormone receptor monoclonal antibodies (mAbs), 
growth factor inhibitors, cytokines, chemokines, 
tyrosine kinase inhibitors, etc [4]. All of these are able 
to interfere with the different pathways by binding key 
signalling molecules. Indeed, these receptor systems 
and their cognate ligands, collaborate in regulating 
cellular programs: quiescence, cell division, terminal 
differentiation, activation of different intracellular 
processes and replacement of old cells or death cells,  
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under normal physiologic conditions. Presence or 
changes in the density of the receptor/ligand systems 
under pathological conditions provide the basis for 
biological therapies and also for nuclear medicine 
imaging. With the availability of the novel molecular 
targeted drugs, it is increasingly important to select the 
patients that might benefit from the targeted therapy. 
This offers a potential role for receptor imaging with 
radiolabelled variants of these targeted drugs or with 
endogenous molecules. The use of new radio- 
pharmaceuticals, could not only provide information on 
patho-biochemical processes but also indicate which 
treatment to apply, when to start it, end it or modify it, 
reducing costs and increasing the benefits. 
CAN NUCLEAR MEDICINE PROVIDE A RATIONALE 
FOR STARTING BIOLOGICAL THERAPIES? 
The diagnosis and follow-up of the pathological 
process in a specific disease is an important goal in 
medicine. Recent advances in the understanding of the 
pathophysiology at molecular level have led to the 
development of peptides, cytokines and mAbs that 
selectively accumulate in target tissue and organs, via 
binding to specific receptors [5, 6]. Biological therapies 
involve the use of biologically derived agents (mAb, 
peptide analogues and drugs) designed to activate the 
patient’s immune system, to treat inflammation and 
specific types of cancer and to control side effects 
caused by the treatments such as immunotherapy and 
chemotherapy. Radiolabelled variants of these agents 
can act as probes for the detection of target cells 
through SPECT and PET scanners. Several 
radiolabelled peptides, cytokines and mAb are used for 
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imaging tumours and inflammation and infection, with 
the intention to improve the monitoring of the efficacy of 
new biological therapies [7]. A nuclear medicine 
approach will have the advantage of not being invasive 
respect to other techniques such as biopsy, 
colonoscopy and others. From this point of view, 
radiolabelled monoclonal antibodies have always 
shown a great potential, but till now only a few reached 
phase III clinical trials. This review provides some 
examples where immunoscintigraphy could give a high 
contribution for therapy decision making and follow-up 
of biological therapies. 
MONOCLONAL ANTIBODIES  
Since their discovery, monoclonal antibodies have 
always been considered “magic bullets” that could 
virtually bind to any antigen with a great potential. 
Indeed, some of them were able to reach the market 
proving a high therapeutic efficacy. However, others 
barely concluded clinical trials or were not able to do so 
because of controversial results. In nuclear medicine, 
therapy decision making and follow-up of therapies 
based on the use of mAbs could be easily achievable 
by radiolabelling the same mAb used for treatment [8]. 
The followings are the most studied radiolabelled mAbs 
that can be used to predict therapeutic response to 
their unlabelled drug. 
Anti-CD20 
Some rheumatologic, autoimmune (AI) and 
lymphoproliferative diseases recognize common 
cellular markers. One of the most investigated, for both 
diagnostic and therapeutic purpose, is represented by 
B cells that can be identified by the expression of the 
antigen CD20 on their surface. The development of 
Rituximab, a mAb directed against CD20, has 
improved the management of several disease in 
particular in patients affected by active rheumathoid 
arthritis (RA) who do not respond to one or more TNF-
alpha antagonist [9] or affected by non-Hodgkin's 
lymphomas (NHL) [10]. It has also been proposed and 
used for the treatment of other autoimmune diseases, 
such as pemphigus vulgaris, primary Sjogren 
Syndrome (pSS) and ANCA-associated vasculitis [11-
13]. Nuclear Medicine can be potentially useful in all 
these pathologies for the in vivo imaging of B cell 
infiltration through the use of radiolabelled-Rituximab 
[14]. Physiologic biodistribution of the radiolabelled 
mAb is shown in Figure 1. 
 
Figure 1: 99mTc-Rituximab scintigraphy in a normal subject 
(left) and in a patient affected by rheumatoid arthritis. In the 
latter there is an evident radiopharmaceutical accumulation in 
the knees and shoulders suggesting active inflammation in 
the joints. 
A study by Malviya et al. demonstrated the utility of 
radiolabelled Rituximab for the assessment and for 
programming a tailored therapy in some AI diseases: 
RA, Psoriatic Arthritis, dermatopolymyositis, pSS, 
Behçet’s disease, relapsing polychondritis and 
sarcoidosis [15]. Scintigrafic images were acquired at 6 
and 20 hours post injection of 99mTc-Rituximab and 
showed increased uptake of the radiopharmaceutical in 
different sites according to the patient’s pathology. For 
example in pSS patients an increased uptake was seen 
in salivary and lachrymal glands, in the five patients 
with active RA and the three patients with Psoriatic 
Arthritis, a mild to moderate uptake was observed in 
the affected joints, in Behçet’s disease 99mTc-Rituximab 
was mainly concentrated in the oral cavity, whereas the 
patient with polychondritis showed an abnormal 
uptakes in thyroid and cricoid cartilages and in a lymph 
node of the neck. The scintigraphy of the patient 
affected by sarcoidosis showed an increased uptake in 
the chest, nasal cavity, lachrymal and salivary glands 
with a pattern of distribution that was similar the one 
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observed with 67Ga-citrate. Interestingly the different 
biodistribution of the radiopharmaceutical seen in these 
different pathologies seems to reflect the different entity 
of B cell infiltration the tissues. 
PET imaging could be potentially applied to AI 
disorders as demonstrated for example by some 
studies in which 124I-Rituximab imaging was performed 
in five patients affected by RA, however its usefulness 
in this specific clinical setting is still not justified by the 
high costs [16]. 
As previously anticipated, anti CD20 mAbs find a 
large application also in hematologic disorders and in 
particular for immunotherapy of relapsing/refractory 
NHL [12, 17-21]. Ibritumomab is a murine mAb directed 
against CD20 similar to Rituximab and it is actually the 
only agent available in Europe. It can be used alone for 
the treatment of NHL or in association with β-emitting 
isotopes for radioimmunotherapy (RIT) mainly using 
90Y (Zevalin®) or 131I and 177Lu [21, 22]. A scintigraphic 
imaging using 111In is recommended for pre-therapy 
assessment of CD20 expression and for prediction of 
subsequent 90Y-Zevalin biodistribution [23, 24]. The 
use of 90Y-Zevalin is now consolidated for the 
management of these kind of patients and it has been 
widely demonstrated that the addition of the 
radioisotope to the mAb increases therapeutic efficacy 
of the anti-CD20 in terms of overall response rate and 
stable responses [25-27]. 
Anti-EGFR 
Cetuximab binds to the epidermal growth factor 
receptor (EGFR), which is variably expressed on 
cellular surface. Among the numerous natural ligands 
of this receptor, we must mention the epidermal growth 
factor (EGF) and transforming growth factor-α (TGFα) 
[28]. This binding initiates several signal transduction 
cascades that principally involve Akt and MAPK 
pathways, leading to DNA synthesis, cell proliferation, 
cell migration and adhesion [29]. Mutations that 
persistently activate EGFR or that cause an 
overexpression of this receptor on cellular surface can 
promote oncogenesis and sustain tumor development. 
These mutations have been observed in several 
cancers of different districts for example colo-rectal, 
lung, head and neck and breast [30-33]. For these 
tumors the development of anti-EGFR therapy could 
represent an important therapeutic tool for personalized 
therapy. Cetuximab is a recombinant, chimeric 
monoclonal antibody directed against the EGFR. It 
prevents the activation of receptor and its dimerization 
resulting in an inhibition of signal transduction and 
consequently in an antineoplastic activity. Cetuximab is 
approved by FDA (Erbitux®) for metastatic colo-rectal 
cancer and squamous cell carcinoma of head and neck 
but several efforts are being directed also in other 
types of cancers. It has been demonstrated that the 
presence of RAS wild type in patients affected by colo-
rectal cancer is associated to a response to Cetuximab, 
while patients with mutated K-RAS seems to have not 
benefits from this therapy [32]. So it could be important 
to have a diagnostic tool that can predict the response 
to therapy in the view of a personalized and targeted 
treatment. Some authors explored the feasibility of 89Zr-
Cetuximab for PET imaging in 10 patients affected by 
colorectal cancer in order to assess the biodistribution 
of the radiopharmaceutical and to predict the success 
of therapy [34]. Despite an important limitation 
represented by the inability to detect liver lesion, in this 
small series 89Zr-Cetuximab seems to provide 
important information regarding tumor expression of 
receptors however these results need to be confirmed 
by larger studies. Some studies on 90Y or 177Lu are also 
emerging in the last years aiming to explore the 
feasibility of radiolabelled Cetuximab as radio- 
immunotherapy [35] but of course they require more 
extensive studies. 
Anti-TNF-α 
Tumor necrosis factor-α (TNF-α) is a pro-
inflammatory cytokine produced by macrophages, 
lymphocytes and other cells in some inflammatory 
chronic conditions such as rheumatoid arthritis (AR), 
ankylosing spondylitis, Crohn’s disease or sarcoidosis. 
Because of high levels of TNF-α in these pathologies, it 
is possible to reveal it using monoclonal antibodies 
(mAbs) in order to do a diagnosis and a decision-
making therapy. 
Two monoclonal antibodies are available against 
both soluble and membrane-bound TNF-α, Infliximab 
(Remicade) and Adalimumab (Humira).  
Infliximab, approved by Food and Drug 
Administration (FDA) in 1998 for the treatment of 
rheumatoid arthritis, is a chimeric monoclonal antibody 
that was directly labelled with 99mTc for imaging 
diseases [36].  
Indeed Conti et al. [37] described a successful case 
report of a man with undifferentiated spondylarthro- 
pathy, performing a scintigraphy at 6 and 24 hours post 
injection of 99mTc-Infliximab. Scintigraphic images 
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showed an accumulation of the radiopharmaceutical in 
the site of lesion. The patient was treated with 
Infliximab and was re-evaluated up to 8 months of 
follow up, showing a complete remission of knee 
arthritis because of absence of TNF-α. 
Another study focused the attention to evaluate the 
production of TNF-α by T helper 1 cells (Th1), in the 
active phase of Crohn’s disease (CD). After in vitro and 
preclinical studies, ten patients underwent 99mTc-
Infliximab scintigraphy to detect TNF-α expression in 
the small bowel. Results showed that scintigraphic 
analysis cannot be considered predictive of clinical 
outcome and it needs further investigations about the 
pathological and molecular mechanisms of anti- TNF-α 
monoclonal antibodies [38].  
Recently, Vis and colleagues [39] performed 
SPECT/CT imaging at 6 and 20 hours after the 
injection of 99mTc-Infliximab in ten patients with 
pulmonary sarcoidosis. Scintigraphic analysis showed 
an accumulation of the radiopharmaceutical in the 
pulmonary tissue, especially in the hilar lymph nodes, 
confirmed by laboratory and clinical parameters too, 
despite of some opposite results between patients. 
Thus, other studies are required to clarify the role of 
99mTc-Infliximab in the anti-TNF-α therapy response. 
Adalimumab is another monoclonal antibody 
directed against both forms of TNF-α, approved by 
FDA in 2002 for the treatment of active rheumatoid 
arthritis and psoriatic arthritis. It is the first fully-human 
mAb and for this reason it is less immunogenic than 
Infliximab. It can be labelled with 99mTc through direct, 
using 2-mercaptoethanol, or indirect method, using the 
bifunctional chelator S-HYNIC [40, 41]. 
99mTc-Adalimumab was investigated by Barrera et 
al. [41] in patients with active rheumatoid arthritis, who 
underwent two scintigraphies, the first at 5 minutes, 4 
and 24 hours post radiopharmaceutical micro-dose 
injection to evaluate the biodistribution and the second 
after two weeks for the specificity and sensitivity for 
inflammation changing. Indeed the first scintigraphy 
revealed a good uptake in inflamed joints compared to 
the absence of uptake in normal joints. Instead, before 
the second scintigraphy, one group was treated with a 
therapeutic dose of unlabelled mAb, the other received 
an intramuscular dose of corticosteroid to reduce 
inflammation. Through this study, authors demonstra- 
ted the specificity and sensitivity of 99mTc-Adalimumab 
to visualize inflammation in patients with AR and it 
could be considered predictive to relevant clinical 
changes.  
In 2008, 99mTc-Infliximab and 99mTc-Adalimumab 
were investigated in a study for therapy-decision 
making and follow up in patients with active AR. 
Patients underwent scintigraphy before and after 3 
months of intra-articular therapy with Infliximab (n=9) or 
systemic therapy with Adalimumab (n=12) [42]. Results 
showed the same biodistribution of two anti-TNF-α 
mAbs, a variable degree of joint uptake has been 
observed, which was not always correlated with joint 
pain or swelling. After the therapy, a reduction of 
uptake of 99mTc-anti-TNF mAb correlated with the 
reduction of clinical symptoms and more benefits were 
observed in patients with higher uptake. However, the 
complete mechanism of uptake of the compound was 
not still clear. Therefore further diagnostic methods 
could help to understand the mechanism. 
Indeed, another mAb, Certolizumab pegol, was 
revealed effective to detect TNF-α by immuno- 
scintigraphy in patients with AR and spondyloarthritis. 
Certolizumab pegol is an engineered humanised mAb 
Fc-free Fab fragment with specificity for human TNF-α 
and it was labelled with 99mTc, using S-HYNIC as 
bifunctional chelator. Scintigraphic imaging was 
performed in 20 patients at 1, 4, 6 and 24 hours after 
the radiopharmaceutical injection, before and after 12 
and 24 weeks treatment with Certolizumab pegol. 
Results showed a good uptake in involved joints, 
especially at 4-6 hours, but also up to 24 hours, with a 
good correlation with clinical evaluation and 
conventional imaging. This study was only a proof-of-
concept, which did not include a negative control to 
observe the presence of unspecific phenomena. So, if 
further studies confirmed these results, 99mTc-
Certolizumab pegol could be a crucial step for 
biological therapy [43]. 
Anti-PD-L1 
One of the newest and most promising pathways 
that can be targeted by immunotherapies is the 
programmed (PD-1) and its ligands, especially PD-L1, 
that are involved in autoimmunity mechanisms. PD-L1 
is overexpressed in the majority of solid tumors 
(including melanoma, non-small cell lung cancer, 
Merkel cell carcinoma, breast cancer, and squamous 
cell carcinomas) and its binding to PD-1 inhibits local T 
cells response to cancer cells. [44] Preclinical studies 
demonstrated that blocking this pathway by using anti-
PD-L1 antibodies could activate autoimmune response 
to tumor, fueling important clinical application for 
cancer therapy. [45] Consequently, the expression of 
PD-L1 by tumor microenvironment can be an essential 
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biomarker to predict response to targeted 
immunotherapies. Tumor with low expression of PD-L1 
will not respond to these drugs. Developing 
radiolabelled anti-PD-L1 tracers can noninvasively 
provide accurate informations about tumor PD-L1 
expression that can otherwise be assessed only 
through biopsy and immunohistochemical staining.  
In vivo imaging of PD-L1 can be very useful both for 
patient selection for targeted immunotherapy and for 
treatment monitoring [46]. It also can be critical for 
clinical development of these drugs, providing 
pharmacokinetics information about whole-body 
biodistribution, tumor uptake and blood half-life. In the 
past few years new tracers have been developed for 
imaging the PD-L1 tumor expression. Josefsson et al. 
[47] developed a murine anti-PD-L1 antibody 
conjugated to Indium-111 for SPECT imaging and 
biodistribution studies in an immune-intact mouse 
model of breast cancer. Also Heskamp et al. [48] used 
anti–PD-L1 antibody PD-L1.3.1 radiolabelled with 
Indium-111; they analyzed tumor targeting by 
SPECT/CT imaging in mice bearing subcutaneous 
cancer xenografts with different PD-L1 expression 
levels. Lesniak et al. [49] assessed 64Cu-Atezolizumab 
for detecting of PD-L1 expression in tumors. 
Atezolizumab is a humanized, human and mouse 
cross-reactive, therapeutic PDL1 antibody that was 
conjugated with DOTAGA, and radiolabelled with 
copper. The resulting 64Cu-Atezolizumab was assessed 
for in vitro and in vivo specificity in multiple cell lines 
and tumors of variable PD-L1 expression. They 
performed PET/CT imaging, biodistribution, and 
blocking studies in NSG mice bearing tumors with 
constitutive PD-L1 expression and in controls. Other 
radiotracers developed for PD-L1 PET imaging and 
biodistribution studies in mice are 64Cu–DOTA–HAC by 
Maute et al. [50] and 64Cu-NOTA-PD-L1 mAb by 
Hettich et al. [46]. 
Anti-HER2 
Trastuzumab is a humanized monoclonal antibody 
against the human epidermal growth factor receptor-2 
with cytotoxic activity on target cells. HER2 is 
expressed in adenocarcinoma and particularly 
overexpressed in breast cancer. The beneficial effects 
on humans of Trastuzumab have been extensively 
reported in the literature, but the HER2 status in 
different lesions may vary due to tumor heterogeneity 
[51]. Therefore, it is important to evaluate the HER2 
status, which is actually done by immunohistochemistry 
on biopsies. Unfortunately, some lesions are not 
accessible and nuclear medicine imaging with 
radiolabelled Trastuzumab may offer an accurate and 
non-invasive evaluation of the receptor expression. 
Indeed, radiolabelled Trastuzumab has been studied 
both in mice and humans with controversial results. In 
particular, in the study by Dijkers et al., in 50% of 
patients, almost 40% of known metastases were not 
detected by PET imaging with 89Zr-Trastuzumab [52]. 
In particular, mainly lesions in the liver were not 
detected because of the high background in the organ, 
typical for radiolabelled mAbs. In other organs, this has 
been explained by the presence of soluble HER2 or 
extensive tumor load, suggesting the need of an 
individualized dosing schedule [53]. However, in a 
study by Gaykema et al. a correlation was observed 
between tumor uptake of radiolabelled Trastuzumab 
and reduction in size of lesions assessed by CT [54]. 
Promising results were also obtained when using 
89Zr-Trastuzumab in combination with 18F-FDG-PET to 
predict the response to ADC trastuzumab-emtansine in 
patients already treated with unlabelled Trastuzumab 
[55]. 
Anti-VEGF 
Bevacizumab is a commercially available mAb that 
binds the vascular endothelial growth factor (VEGF), 
which is involved in neoangiogenesis of many cancer 
types promoting metastatization. Therefore, 
Bevacizumab has been proposed as an anti-
angiogenic treatment for aggressive breast tumors, 
ductal carcinoma and other cancer types. Whereas 
HER2 is bound on the plasma membrane, VEGF is a 
soluble factor, although some isoforms may be bound 
to extracellular matrix. However, it has been reported 
that VEGF concentration in metastases is greatly 
increased and this allows the use of radiolabelled 
Bevacizumab to evaluate the ligand expressions into 
metastatic lesions. The mAb has been radiolabelled 
with 99mTc, 111In or 89Zr and tested in animal models 
and humans with controversial results. In melanoma 
and primary breast cancer, it was able to visualize all 
known lesions, but, when focusing on lymph nodes, 
only 4 out of 14 were detected [54, 56]. In addition, 
uptake of radiolabelled Bevacizumab and concentration 
of VEGF into lesions not always correlated and it was 
dependent on the analysed isoform. Variable uptake 
was observed in patients affected by neuroendocrine 
tumors and renal cell carcinoma. In addition, no 
correlation between baseline tumor uptake and change 
of tumor size as assessed by CT was observed. In lung 
cancer, the correlation between radiolabelled mAb 
uptake and response to treatment was investigated in 7 
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patients with unsatisfactory results [57]. The authors 
hypothesised that it was not possible to distinguish 
between the therapeutic contribution of Bevacizumab 
or chemotherapy, limiting the study. The use of 
radiolabelled Bevacizumab for evaluation of therapeutic 
efficacy of anti-angiogenic drugs was also explored in 
renal carcinoma by Oosting et al. Again, it was not 
possible to correlate imaging results with time to 
progression [58]. In general, Bevacizumab uptake 
strongly depended on tumor type, reflecting different 
expression of VEGF by different cancer. In addition, 
inter- and intra-patient tumor heterogeneity was 
observed. 
CONCLUSIONS  
Because of the increasing availability of biological 
therapies based on the use of mAbs, 
immunoscintigraphy with the same radiolabelled drugs 
may help physicians in therapy decision making and 
follow-up. A wide range of mAbs has been 
radiolabelled and tested in different diseases, but till 
now none has entered in clinical practice. This is 
because many pathological conditions and antigen 
status have not been completely elucidated yet. This is 
in accordance with results from clinical trials with the 
unlabelled drugs that led physicians to use them in 
combination with other therapies rather than alone. 
This could be also the cause of the lack of correlation 
between imaging results and response to therapy, 
since the combination with chemotherapy or secondary 
effects on non-target cells (like enhanced permeability 
effects) may alter the biodistribution and uptake of the 
radiopharmaceuticals. This is crucial, since the retained 
biodistribution is one of the requirements that a 
radiolabelled mAb should meet to evaluate response to 
therapy with the unlabelled molecule. Intra- and inter-
patient heterogeneity is another challenge, since some 
lesions may be undetected and combination with other 
imaging modalities like CT or MRI could be helpful. 
Once these issues will be solved, immunoscintigraphy 
will certainly become a reliable non-invasive technique 
to safely predict therapy outcome and follow-up 
treatment. 
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